Holen Sie sich die Stockscreener-App
296.41
0.44%
1.31
Handel nachbörslich:
296.41
Schlusskurs vom Vortag:
$295.10
Offen:
$297.01
24-Stunden-Volumen:
901.31K
Relative Volume:
1.00
Marktkapitalisierung:
$14.15B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$-182.84M
KGV:
-78.83
EPS:
-3.7603
Netto-Cashflow:
$391.29M
1W Leistung:
+1.70%
1M Leistung:
+32.15%
6M Leistung:
+66.07%
1J Leistung:
+82.07%
1-Tages-Spanne:
$295.93
$303.31
1-Wochen-Bereich:
$289.07
$303.31
52-Wochen-Spanne:
$144.26
$303.31
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
296.41 | 13.91B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-05-29 | Hochstufung | CLSA | Hold → Outperform |
| 2026-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
What Does Charles River Laboratories International (CRL) Gain From This Vaccine Collaboration? - simplywall.st
Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development? - Yahoo Finance
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running? - TradingView
Charles River Labs stock holds near fresh 52-week high after strong Q2 earnings - Ad-hoc-news.de
Are Options Traders Betting on a Big Move in Charles River Stock? - TradingView
Charles River Gains 88.6% in a Year: What's Driving the Rally? - Yahoo Finance
Madison Asset Management LLC Invests $3.81 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs CEO Birgit Girshick Gifts 528 Shares, Retains Significant Ownership - Kalkine Media
Charles River Laboratories Director Nancy C. Andrews Reports Form 4 Filing on Stock Option Exercise and Sale - Kalkine Media
Charles River Labs CEVP Parisotto sells $599,710 in shares By Investing.com - Investing.com Australia
Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares - MarketBeat
Charles River (NYSE: CRL) CEO makes 528-share gift of common stock - Stock Titan
Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat
Charles River Labs CEVP Parisotto sells $599,710 in shares - Investing.com
Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing - marketscreener.com
Charles River (NYSE: CRL) insider sells 2,039 shares in 10b5-1 plan - Stock Titan
Charles River (NYSE: CRL) director exercises options, sells 573 shares - Stock Titan
Charles River Labs stock hits fresh 52-week high as Medigen vaccine deal boosts sentiment - Ad-hoc-news.de
Charles River Laboratories stock hits 52-week high at $294.68 By Investing.com - Investing.com Nigeria
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing - BioSpace
Charles River Laboratories International, Inc. and Medigen Vaccine Biologics Corp. Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing - marketscreener.com
MEX:CRL EV-to-OCF: 27.30 — 36% Above Median - GuruFocus
Is Charles River Laboratories International Inc (CRL) Overvalued - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River (NYSE: CRL) officer to sell 2,039 shares after option exercise - Stock Titan
Charles (CRL) Snapshot: Moves 4.77% Up to $292.52 in the Latest Session; Levels: the $277.89 to $307.15 Range Remains in FocusMotive Wave - Vinanet
Charles (CRL) Results Versus Estimates: Profit Per Share Surpasses Its Benchmark at the Close; Trading Move - Vinanet
Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued? - simplywall.st
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Labs stock reaches new 12-month high as 2026 guidance lifts expectations - Ad-hoc-news.de
Charles River (NYSE: CRL) investor to sell 573 shares via UBS - Stock Titan
Resilient Charles River Labs stock hits new 12-month high as Q2 revenue tops $1 billion - AD HOC NEWS
Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month HighHere's Why - MarketBeat
Birgit Girshick maps out Charles River's post-divestiture future: re-accelerating growth and a lighter portfolio - The Pharma Letter
CRL Q2 2026 Earnings: EPS Surge of 9.23% Beats Estimates as Shares Nudge LowerEarnings Volatility Report - Vinanet
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing? - Moomoo
Handelsbanken Fonder AB Increases Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Lowered 2026 EPS Outlook and Rebounding Demand Could Be A Game Changer For Charles River (CRL) - simplywall.st
If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Birgit Girshick Sells 6,500 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Charles River Labs (CRL) CEO exercises 6,500 options and sells shares under 10b5-1 plan - Stock Titan
Charles River (CRL) executive Parisotto exercises options, sells 3,714 shares under 10b5-1 plan - Stock Titan
Invesco reports 2.98M-share stake in Charles River Laboratories (CRL) - Stock Titan
Charles River Laboratories stock hits 52-week high at $285.13 - Investing.com
Charles River Laboratories stock hits 52-week high at $285.13 By Investing.com - Investing.com Australia
Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Charles River Laboratories International, Inc. $CRL Shares Sold by Pacer Advisors Inc. - MarketBeat
Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells $7,901,575.00 in Stock - MarketBeat
Charles River Laboratories (CRL) EVP LaPlume reports bona fide gift of 257 shares - Stock Titan
Charles River (CRL) director James C. Foster exercises options and sells 28,733 shares - Stock Titan
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):